medigraphic.com

2018, Number 4

<< Back Next >>

Rev Educ Bioquimica 2018; 37 (4)

Estudio de las células cancerosas y su activación celular en el cáncer de mama

López-Naranjo F, Ávila-Álvarez EP, Guadarrama-Flores B, Córdova-Moreno R, Hernández-Rodríguez NA

Language: Spanish
References: 30
Page: 100-110
PDF size: 318.26 Kb.


ABSTRACT

25 new cases of breast cancer (death rate of 100,000 women over 25 years) are diagnosed in Mexico. The leading cause of death by cancer is metastasis, where Thrombin and its receptor, PAR1, constitute a system relevant receptor/growth factor in the invasive cancer process. The objective of this study was to determine the activity of the ERKs in relation to the invasive potential of two cell lines of breast cancer associated with the expression of Thrombin receptor PAR1, and know the contribution specified in the MAP kinase inhibitor specific. A significant increase of ERK2 were found in the two cell lines. This suggests that the differences between the activation of ERKs isoforms, could reveal some type of regulation among them.


REFERENCES

  1. Abdel Z AM, Eldeib AM. (2016) Breast cancer classification using deep belief networks. Expert Systems with Applications. 46: 139– 144.

  2. DeSantis C, Siegel R, Jema A. American Cancer Society. (2012) Breast cancer facts and figures 2011–2012. Atlanta: American Cancer Society, Inc.; 1-36.

  3. Sánchez B JJ. (2015) Mortality trends and risk of dying from breast cancer in the 32 states and 7 socioeconomic regions of Mexico, 2002- 2011. Epidemiology Biostatistics and Public Health. 12(1): 1-12.

  4. Zeisberg M, Neilson EG. (2009) Biomarkers for epithelial-mesenchymal transitions. J Clin Invest. 119 (6): 1429–1437.

  5. “Estadísticas a propósito del día mundial de la lucha contra el cáncer de mama”. (2015) INEGI Aguascalientes, Ags.

  6. Lim, HC, Multhaupt H AB, Couchman JR. (2015) Cell surface heparin sulfate proteoglycans control adhesion and invasion of breast carcinoma cells. Molecular Cancer 14(1):15.

  7. Hermida LI, Sánchez TE, Nerín SC, Cordero BR, Mora EI, Pinar SJ. (2016) Marcadores Tumorales. REV CLÍN MED FAM; 9(1): 31-42.

  8. Lidfeldt J, Bendahl PO, Forsare C, Malmström P, Fernö M., Belting M. (2015) Protease activated receptors 1 and 2 correlate differently with breast cancer aggressiveness depending on tumor ER status. PLOS ONE. 10(8): e0134932.

  9. Marie KF, Arreola OH, Velázquez E, Dorantes J, Méndez O, Ávila BL. (2009) El costo de la atención médica del cáncer mamario: el caso del Instituto Mexicano del Seguro Social. Rev. Salud Pública de México. vol. 51 supl.2

  10. Ichimura K, Shinozaki K, Tena G, Sheen J, Henry Y, Champion A, Kreis M, Zhang S, Hirt H, Wilson C, Heberle BE, Ellis BE., Morris PC, Innes RW, Ecker JR, Scheel D, Klessig DF, Machida Y, Munsy J, Ohashi Y and Walker JC. (2002) Mitogen-activated protein kinase cascades in plants: a new nomenclature. Trends Plant Sci 7: 301-308.

  11. Santillán B JG, Quiroz OH, Mendieta ZH, Gómez O LM. (2013) Expresión génica y receptores hormonales en cáncer mamario. “El camino hacia la búsqueda de terapias preventivas”. Revista de Medicina e investigación 1(1): 1-42.

  12. Kamath L, Meydani A, Foss F, Kuliopulos A. (2001) Signaling from protease activated receptor-1inhibits migration and invasion of breast cancer cells. Cancer Res 61: 5933.

  13. Even RS, Uziely B, Cohen P, Grisaru GS, Maoz M, Ginzburg Y, Reich R, Vlodavsky I, Bar SR. (1998) Thrombin receptor over expression in malignant and physiological invasion process. Nat Med 4(8):909-914.

  14. Ceballos CG, Maldonado LV, Hernández RN. (2007) Signaling induced by PAR1 on breast cancer cell lines is correlating with its invasive potential. BMC Cancer. 7(1):A10. doi:10.1186/1471-2407-7-S1-A10

  15. Ohshiro K, Bui N TM, Natha R SD, Schwartz AM, Levine P, Kumar R. (2012) Thrombin stimulation of inflammatory breast cancer cells leads to aggressiveness via the EGFRPAR1- pak1 pathway. International Journal of Biological Markers. 27(4):e305-e313.

  16. Maiello MR, D’Alessio A, Bevilacqua S, Gallo M, Normanno N, De Luca A. (2015) EGFR and MEK Blockade in Triple Negative Breast Cancer Cells. Journal of Cellular Biochemistry. 116(12):2778-2785.

  17. Ortiz M JM. (2009) Proteína quinasas como dianas farmacológicas. Real academia nacional de farmacia. Farmacia 11 28004 Madrid. Spain DOI: http://dx.doi.org/ES/monoranf. v0i0.808:15-45.

  18. Roskoski RJ. (2012) ERK1/2 MAP kinases: Structure, function, and regulation. Pharmacological Research. 66:105– 143.

  19. Hsu YL, Hou MF, Kuo PL, Huang YF, Tsai EM. (2013) Breast tumor-associated osteoblastderived CXCL5 increases cancer progression by ERK/MSK1/Elk1/snail signaling pathway. Oncogene 32(37): 4436–4447.

  20. Roser B, Pouysségur J, and Lenormand P. (2016) ERK1 and ERK2 Map Kinases: Specific Roles or Functional Redundancy?. Front Cell Dev Biol. 4: 53:1-23. doi: 10.3389/ fcell.2016.00053

  21. Smith BN, Burton LJ, Henderson V, Randle DD, Morton DJ, Smith BA. Taliaferro SL, Nagappan, P, Yates C, Zayzafoon, M, Leland WK, Chung VA, Odero M. (2014) Snail Promotes Epithelial Mesenchymal Transition in Breast Cancer Cells in Part via Activation of Nuclear ERK2. PLOS ONE. 9 (8):e104987.

  22. Kabir MH, Suh EJ, Lee C. (2012) Comparative phosphoproteome analysis reveals more ERK activation in MDA-MB-231 than in MCF-7. International Journal of Mass Spectrometry. (309): 1– 12.

  23. Chu HW, Cheng CW, Chou WC, Hu LY, Wang HW, Hsiung CN, Hsu HM, Wu PE, Hou MF, Shen CY, Yu JC. (2014) A novel estrogen receptor-microRNA 190a-PAR-1-pathway regulates breast cancer progression, a finding initially suggested by genome-wide analysis of loci associated with lymph-node metastasis. Human Molecular Genetics. 23 (2):355-367.

  24. Bradford M MA. (1976) Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding. Analytical Biochemistry. (72): 248-254.

  25. Kamath L, Meydani A. (2001) Signaling from Protease Activated Receptor-1 inhibits migration and invasion of breast cancer cells. Cancer Res. (61): 5933-5940.

  26. Ray LB, Sturgill TW. (1998) Insulin-stimulated microtubule-associated protein kinase is phosphorylated on tyrosine and threonine in vivo. Proceedings of the National Academy of Sciences of the United States of America. (85):3753–3757.

  27. Roskoski, JR. (2012) MEK1/2 dual-specificity protein kinases: structure and regulation. Biochemical and Biophysical Research Communication 417:5–10.

  28. Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, Wallasch Ch, Ullrich A. (1999) EGF-receptor transactivation by G-proteincoupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature. 402:884-888.

  29. Prenzel N, Zwick E, Leserer M, Ullrich A. (2000) Tyrosine kinase signalling in breast cancer Epidermal Growth factor receptor: convergence point for signal integration and diversification. Breast Cancer Res. 2:184-190.

  30. wLefloch R, Pouysségur J, Lenormand P. (2008) Single and combined silencing of ERK1 and ERK2 reveals their positive contribution to growth signaling depending on their expression levels. Molecular and Cellular Biology. 28: 511–27.




2020     |     www.medigraphic.com